Eli Lilly Partners With Walmart To Expand Access To Popular Weight-loss Drug
- Zepbound vials will be offered for pick-up at Walmart pharmacies nationwide by mid-November.
- This marks LillyDirect’s first retail collaboration and is aimed at offering patients flexibility in how they access the drug, the company said.
Eli Lilly and Company (LLY) on Wednesday announced a collaboration with Walmart Inc. (WMT) to expand access to lower pricing for its popular weight-loss drug Zepbound, available through its digital health platform LillyDirect.
Zepbound vials will be offered for pick-up at Walmart pharmacies nationwide by mid-November, the company said. This marks LillyDirect’s first retail collaboration and is aimed at offering patients flexibility in how they access the drug, the company said.
Zepbound single-dose vials will be available in all approved strengths, with the lowest dose starting at $349 per month with self-pay at Walmart pharmacies, the company said.
Zepbound, containing Tirzepatide, reduces appetite and the amount a person eats to induce weight loss. Lilly started offering Zepbound at discounted prices to cash-paying customers on LillyDirect in June to expand access.
Get updates to this developing story directly on Stocktwits.
